来自Andrographis paniculata的部分和纯化合物的抗糖尿病性质
Bishwajit Bokshi1, Hui Chen2, Alison T Ung1
1School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, New South Wales, Australia.
Natural product research
|December 15, 2023
概括
安德罗格拉菲斯 (Andrographis paniculata) 的分量显著增加葡萄糖的吸收,并减少脂肪细胞中的脂质. 孤立的化合物显示出强大的抗糖尿病作用,支持其用于2型糖尿病管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 代谢疾病 代谢疾病
背景情况:
- * Andrographis paniculata 传统上用于各种疾病.
- * 它在治疗2型糖尿病方面的潜力需要科学验证.
- * 无叶绿素提取物被探索以确定生物活性成分.
研究的目的:
- * 调查A. paniculata无叶绿素部分对3T3-L1脂肪细胞的葡萄糖吸收和脂质减少的影响.
- * 识别和描述导致这些作用的活性化合物.
- * 评估隔离化合物的抗糖尿病潜力.
主要方法:
- * A. paniculata 提取物的制备和分成.
- * 在3T3-L1脂肪细胞中评估葡萄糖吸收.
- *在3T3-L1脂肪细胞中进行脂质积累测定.
- * 气相色谱-质谱 (GC-MS) 用于化学分析.
- * 纯化合物的隔离和结构阐明.
主要成果:
- * 酸性,基性和中性分量显著增强脂肪细胞中的葡萄糖吸收,优于原始提取物.
- *GC-MS分析确定了具有潜在抗糖尿病活性的化合物.
- * 分离了三种化合物,其中包括一种新型化合物 (3-epi-11,12-didehydro-14-deoxyandrographolide).
- *单独的化合物14-deoxyandrographolide和新型化合物在葡萄糖吸收方面表现出与甲福林相当的疗效.
- * 这些化合物还减少了脂肪细胞中的脂质积累.
结论:
- * A. paniculata 的无叶绿素分离物具有显著的抗糖尿病特性.
- * 特定的分离化合物显示出有前途的降血糖和降脂效应.
- * A. paniculata 是开发新型抗糖尿病药物的潜在来源.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Oral Hypoglycemic Agents: Sulfonylureas
211
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
211
Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327


